tiprankstipranks
AEON Biopharma (AEON)
NYSE MKT:AEON
US Market
Holding AEON?
Track your performance easily

AEON Biopharma (AEON) Income Statement

92 Followers

AEON Biopharma Income Statement

Last quarter (Q3 2024), AEON Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, AEON Biopharma's net income was $-6.17M. See AEON Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 22.32M$ -29.56M$ 48.43M$ 1.94M$ 3.59K
Operating Income
$ -22.32M$ 29.56M$ -48.43M$ -1.94M$ -3.59K
Net Non Operating Interest Income Expense
$ 2.29M-$ 3.71M$ 79.69K$ 0.00
Other Income Expense
$ 31.16M$ -2.85M$ -4.13M$ -10.06M-
Pretax Income
$ -75.99M$ 24.05M$ -52.56M$ 8.20M$ -3.59K
Tax Provision
$ 629.09K-$ 883.33K$ -389.81K-
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -61.55M$ -20.34M$ -52.56M$ 8.20M$ -3.59K
Basic EPS
$ -2.63$ 0.65$ 0.29$ 0.52$ >-0.01
Diluted EPS
$ -2.63$ 0.65$ 0.29$ 0.52$ >-0.01
Basic Average Shares
$ 155.34M$ 37.16M$ 27.60M$ 31.31M$ 34.50M
Diluted Average Shares
$ 155.34M$ 37.16M$ 27.60M$ 31.31M$ 34.50M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 22.32M$ -29.56M$ 48.43M$ 1.94M$ 3.59K
Net Income From Continuing And Discontinued Operation
$ -129.27M$ -20.34M$ -52.56M$ 8.20M$ -3.59K
Normalized Income
$ -82.38M$ 19.00M-$ 7.81M$ -3.59K
Interest Expense
-----
EBIT
$ 10.79M$ -20.34M$ -52.56M$ 8.20M$ -3.59K
EBITDA
$ 10.81M$ -20.34M$ -52.49M$ 8.20M$ -3.59K
Currency in USD

AEON Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis